Researchers based at Uppsala University in Sweden have created an adeno-associated viral (AAV) vector treatment for glioma or glioblastoma that extended survival in a mouse model of the brain cancer. Writing in the May 11, 2023, issue of Cancer Cell, the researchers reported that by introducing an inflammatory protein known as LIGHT to the tumor microenvironment using the AAV treatment, the mice were better able to fight the cancer.